According to the ”Global Non-Hodgkin Lymphoma Therapeutics Market 2014-2018”
report Non-Hodgkin lymphoma (NHL) is a condition of the human body
leading to the production of abnormal lymphocytes. In normal
circumstances, the lymphocytes grow and die. However, in NHL they do not
die; instead they grow and further divide. NHL can begin either in the
T-cells or B-cells, though mostly it begins in the B-cells. The location
of NHL is generally in the lymph nodes, but it can also spread to the
body’s lymphatic system. It has many symptoms, of which swelling in the
lymph nodes, abdominal pain, chest pain, cough, fever, fatigue, and
night sweats are the most prominent. The causes of this disease are
still unknown to scientists. NHL is linked with risk factors such as the
overuse of immunosuppressant drugs, viruses such as HIV or
Epstein-Barr, and bacteria such as Helicobacter pylori. NHL can be
diagnosed by urine tests, physical examination for the enlargement of
the lymph nodes, imaging tests (scans) such as magnetic resonance
imaging (MRI) or computerized tomography (CT), and biopsy tests.
Analysts
forecast the Global Non-Hodgkin Lymphoma Therapeutics market will grow
at a CAGR of 7.03 percent over the period 2014-2018.
Covered in this Report
This
report covers the present scenario and the growth prospects of the
Global Non-Hodgkin Lymphoma Therapeutics market for the period
2014-2018. The Global Non-Hodgkin Lymphoma Therapeutics market will
observe a high growth in the forecast period. It is due to the
availability of the biosimilars at a reduced price across the NHL
market. This will be mainly due to the growth of the drug Rituxan in the
global market. Apart from that, the market will also grow as a result
of the improved diagnostic techniques to detect NHL. Besides, the
increase in public awareness about NHL and robust drug pipeline for the
treatment of NHL are the major influencers in the growth of the Global
Non-Hodgkin Lymphoma Therapeutics market.
Global Non-Hodgkin
Lymphoma Therapeutics Market 2014-2018, has been prepared based on an
in-depth market analysis with inputs from industry experts. The report
covers the Americas, and the EMEA and APAC regions; it also covers the
Global Non-Hodgkin Lymphoma Therapeutics market landscape and its growth
prospects in the coming years. The report also includes a discussion of
the key vendors operating in this market.
Key Vendors
Bristol Myers Squibb Co.
Celgene Corp.
Eli Lilly and Co.
F. Hoffman La-Roche Ltd.
GlaxoSmithKline plc
Celgene Corp.
Eli Lilly and Co.
F. Hoffman La-Roche Ltd.
GlaxoSmithKline plc
Other Prominent Vendors
Accredo Health Group Inc.
Baxter International Inc.
Bayer AG
Cephalon Inc.
Eisai Pharmaceuticals Inc.
Genelabs Technologies Inc.
Hospira Inc.
Johnson & Johnson
Merck & Co. Inc.
Millenium Pharmaceuticals Inc.
Pacira Pharmaceuticals Inc.
Pfizer Inc.
Sanofi SA
Teva Pharmaceuticals Inc.
Baxter International Inc.
Bayer AG
Cephalon Inc.
Eisai Pharmaceuticals Inc.
Genelabs Technologies Inc.
Hospira Inc.
Johnson & Johnson
Merck & Co. Inc.
Millenium Pharmaceuticals Inc.
Pacira Pharmaceuticals Inc.
Pfizer Inc.
Sanofi SA
Teva Pharmaceuticals Inc.
